Resectable Esophageal Cancer Clinical Trial
Official title:
Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer
Despite the availability of several preoperative diagnostic techniques, accurate pretreatment staging of esophageal cancer (EC) remains challenging. Therefore, The investigators evaluated the prognostic significance of circulating tumor cells (CTCs) in patients with EC.
| Status | Completed |
| Enrollment | 123 |
| Est. completion date | April 2014 |
| Est. primary completion date | April 2014 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - > 18 years - resectable esophageal cancer Exclusion Criteria: - < 18 years - esophageal cancer with preoperative distant metastases |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| Germany | University Hospital Hamburg-Eppendorf | Hamburg |
| Lead Sponsor | Collaborator |
|---|---|
| Universitätsklinikum Hamburg-Eppendorf |
Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | overall survival | 2 years | Yes | |
| Secondary | recurrence-free survival | 2 years | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03490292 -
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00827671 -
Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT04006041 -
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
|
Phase 2 | |
| Recruiting |
NCT05307835 -
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
|
Phase 1 |